Rating Change
BMO Capital reiterated its Outperform rating on Protagonist Therapeutics, Inc. (NASDAQ:PTGX) on August 17, 2026.
reiterateNASDAQ:PTGX
BMO Capital Reiterates Outperform Rating on Protagonist Therapeutics, Inc. (PTGX)
BMO Capital reiterated its Outperform rating on Protagonist Therapeutics, Inc. (NASDAQ:PTGX) on August 17, 2026.
At publication ·
What changed
Protagonist Therapeutics, Inc. (NASDAQ:PTGX) · reiterate
- Firm
- BMO Capital
- Rating
- Outperform to Outperform
- Price at event
- $158.62
- Market capitalization
- $5.8B
At a glance
Key takeaways
- BMO Capital reiterated an Outperform rating on Protagonist Therapeutics (PTGX) on August 17, 2026, with the stock trading at $158.62 and a market capitalization of $5.8 billion.
Market Context
Protagonist Therapeutics, Inc. operates in the Healthcare sector. The stock currently trades at $158.62 with a market capitalization of $5.8B.
Analyst coverage from BMO Capital provides professional research and price targets that many institutional investors reference when making allocation decisions. The consensus of analyst opinions — along with the range of price targets — helps frame market expectations for Protagonist Therapeutics, Inc.
Analyst ratings and price targets are one input among many for investment decisions. Historical studies show that consensus analyst recommendations have mixed predictive power on their own, but significant changes in consensus — such as multiple upgrades or downgrades in a short period — can be more meaningful signals.
Recent Analyst Activity for Protagonist Therapeutics, Inc.
Among the 10 most recent ratings: 10 Buy, 0 Hold, 0 Sell.
| Date | Firm | Rating | Price Target |
|---|---|---|---|
| Aug 17, 2026 | BMO Capital | Outperform | N/A |
| Aug 10, 2026 | Wedbush | Outperform | N/A |
| Aug 10, 2026 | Truist Securities | Buy | N/A |
| Aug 10, 2026 | Goldman Sachs | Buy | N/A |
| Aug 06, 2026 | Barclays | Overweight | N/A |
Related Tools: Analyst Ratings Dashboard | View PTGX Stock Page
Frequently Asked Questions
What does the Outperform rating mean for PTGX?
A rating of Outperform from BMO Capital reflects the analyst's outlook on Protagonist Therapeutics, Inc. (NASDAQ:PTGX). Analyst ratings are one factor investors consider alongside earnings, valuation, and sector trends.
Where can I find more analyst ratings?
Browse recent upgrades and downgrades on our Analyst Ratings Dashboard or the PTGX forecast page.